Assembly Biosciences
ASMB
72 hedge funds and large institutions have $432M invested in Assembly Biosciences in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
67% more capital invested
Capital invested by funds: $259M → $432M (+$173M)
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
11% more funds holding
Funds holding: 65 → 72 (+7)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.09% less ownership
Funds ownership: 6.03% → 5.94% (-0.09%)
50% less call options, than puts
Call options by funds: $1.84M | Put options by funds: $3.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$7.66M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.28M |
| 3 |
Renaissance Technologies
New York
|
+$998K |
| 4 |
BlackRock
New York
|
+$697K |
| 5 |
PP
PDT Partners
New York
|
+$550K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$8.66M |
| 2 |
Jennison Associates
New York
|
-$4.6M |
| 3 |
O
OrbiMed
New York
|
-$3.59M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.71M |
| 5 |
Millennium Management
New York
|
-$1.1M |
ASMB Hedge Fund Activity: Q3 2017 in Review
72 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2017, worth a combined $432M — up 67% from $259M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ASMB positions and 5 closed out — a net gain of 8 holders — while 25 added to existing stakes and 22 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $7.66M. The largest seller was QVT Financial, cutting an estimated $8.66M.
- 72 institutional investors held Assembly Biosciences (ASMB) as of Q3 2017, up from 65 in Q2 2017.
- Funds reported $432M of Assembly Biosciences stock for Q3 2017, up 67% quarter-over-quarter.
- 13 funds opened new Assembly Biosciences positions in Q3 2017 and 5 closed out, a net change of +8 holders.
- The largest Assembly Biosciences buyer in Q3 2017 was Avoro Capital Advisors, an estimated $7.66M added.
- The largest Assembly Biosciences seller in Q3 2017 was QVT Financial, an estimated $8.66M sold.
Based on aggregated 13F filings for Q3 2017.